SEC Form 4 · accession 0001209191-18-038852
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Fust
Director
Period of report
Jun 19, 2018
Accepted (ET)
Jun 20, 2018 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 19, 2018 | A | 3,000 | $0.00 | A | 11,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $80.69 | Jun 19, 2018 | A | 5,000 | A | — | Jun 19, 2028 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019.
- F2The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019.